Calendar

Apr
30
Fri
2021
Racial Equity Challenge: Race in society @ Zoom
Racial Equity Challenge: Race in society
Apr 30 @ 12:00 pm – 1:00 pm Zoom
Racial Equity Challenge: Race in society @ Zoom

Targeted violence continues against Black Americans, Asian Americans, and all people of color. The department of radiology diversity committee is running a racial equity challenge to raise awareness of systemic racism, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles, podcasts, videos, etc., from which they can choose, with the “challenge” of engaging with one to three media sources prior to our session (some videos are as short as a few minutes). Participants will meet in small-group breakout sessions to discuss what they’ve learned and share ideas.

Please reach out to Marta Flory, flory@stanford.edu with questions. For details about the session, including recommended resources and the Zoom link, please reach out to Meke Faaoso at mfaaoso@stanford.edu.

May
11
Tue
2021
Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Michael Berger, Ph.D.
May 11 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: “Building a Scalable Clinical Genomics Program: How tumor, normal, and plasma DNA sequencing are informing cancer care, cancer risk, and cancer detection”

 

Michael Berger, Ph.D.

Elizabeth and Felix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center

 

Zoom Details
Meeting URL: https://stanford.zoom.us/s/92559505314
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 925 5950 5314
Passcode: 418727

11:00am – 12:00pm Seminar & Discussion
RSVP Here

 

ABSTRACT
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of oncogenomic mutations that can be targeted therapeutically. To accelerate enrollment to clinical trials of molecularly targeted agents and guide treatment selection, we have established a center-wide, prospective clinical sequencing program at Memorial Sloan Kettering Cancer Center using a custom, paired tumor-blood normal sequencing assay (MSK-IMPACT), which we have used to profile more than 50,000 patients with solid tumors. Yet beyond just the characterization of tumor-specific alterations, the inclusion of blood DNA has readily enabled the identification of germline risk alleles and somatic mutations associated with clonal hematopoiesis. To complement this approach, we have also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for cancer detection, surveillance, and treatment selection and monitoring. In my talk, I will describe the prevalence of somatic and germline genomic alterations in a real-world population, the clinical benefits of cfDNA assessment, and how clonal hematopoiesis can inform cancer risk and confound liquid biopsy approaches to cancer detection.

 

ABOUT
Michael Berger, PhD, holds the Elizabeth and Felix Rohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, a multidisciplinary initiative to promote precision oncology through genomic analysis to guide the diagnosis and treatment of cancer patients. He is also an Associate Attending Geneticist in the Department of Pathology with expertise in cancer genomics, computational biology, and high-throughput DNA sequencing technology. His laboratory is developing experimental and computational methods to characterize the genetic makeup of individual cancers and identify genomic biomarkers of drug response and resistance. As Scientific Director of Clinical NGS in the Molecular Diagnostics Service, he oversees the development and bioinformatics associated with clinical sequencing assays, and he helped lead the development and implementation of MSK-IMPACT, a comprehensive FDA-authorized tumor sequencing panel that been used to profile more than 60,000 tumors from advanced cancer patients at MSK. The resulting data have enabled the characterization of somatic and germline biomarkers across many cancer types and the identification of mutations associated with clonal hematopoiesis. Dr. Berger also led the development of a clinically validated plasma cell-free DNA assay, MSK-ACCESS, which his laboratory is using to explore tumor evolution, acquired drug resistance, and occult metastatic disease. He received his Bachelor’s Degree in Physics from Princeton University and his Ph.D. in Biophysics from Harvard University.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

May
18
Tue
2021
PHIND Seminar - Patricia A. Deverka, MD, MS, MBE & Kathryn A. Phillips, PhD @ Zoom - See Description for Zoom Link
PHIND Seminar – Patricia A. Deverka, MD, MS, MBE & Kathryn A. Phillips, PhD
May 18 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
PHIND Seminar - Patricia A. Deverka, MD, MS, MBE & Kathryn A. Phillips, PhD @ Zoom - See Description for Zoom Link

PHIND Seminar Series: Multi-Cancer Early Detection Screening Tests – “Liquid Biopsy Tests” – Are Here – But Will Payers Provide Insurance Coverage?

 

Patricia A. Deverka, MD, MS, MBE
Executive Director
Deverka Consulting, LLC

 

Kathryn A. Phillips, PhD
Professor of Health Economics and Health Services Research
Founding Director, UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)

 

Location: Zoom
Webinar URL: https://stanford.zoom.us/s/99194110894
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Webinar ID: 991 9411 0894
Passcode: 044958

11:00am – 12:00pm Seminar & Discussion
RSVP Here

 

ABSTRACT
The emergence of Multi-Cancer Early Detection Screening Tests (MCED) – “liquid biopsy screening tests” – has generated enormous interest because they could fundamentally shift how cancer screening is done. One company is already offering an MCED test for clinical use as a “lab developed test” (LDT) – and thus addressing the question of “who will pay” has become urgent. These tests offer potentially transformative screening and clinical benefits, but their characteristics present unique challenges to payer coverage decision-making and generate concerns about the potentially high cost of widespread adoption.

We will present our ongoing work on examining the unique challenges that MCED present for payer coverage decision-making, drawing on our extensive experience with coverage and reimbursement for new technologies. We will focus on identifying the evidence generation strategies that could be pursued now to inform payer decision-making so that coverage policies can be developed that are appropriate and equitable for this ground-breaking technology.

 

ABOUT PATRICIA A. DEVERKA
Dr. Deverka is the Executive Director at Deverka Consulting, LLC where she focuses on helping biotechnology companies and start-ups develop evidence to support payer coverage and clinical adoption of innovative technologies.  Her most recent projects have focused on breakthrough tests and drugs focused on population genomic screening, cancer, and ultra-rare disorders.  Prior to starting her consulting practice, Dr. Deverka has worked in the fields of health economics and outcomes research in both non-profit and for-profit settings as a researcher, educator, and department head. She has extensive experience with patient-centered outcomes research, drug and diagnostic reimbursement planning, cost- effectiveness analysis, and bioethical issues surrounding the use of new technologies. While working in academia and several non-profit firms, she has participated in numerous NIH-funded studies to evaluate policy barriers to clinical integration of new genomic technologies and has published extensively on strategies to promote evidence generation and data sharing. She is a member of the National Human Genome Research Institute (NHGRI)’s Genomic Medicine Work Group and serves as a member of NHGRI’s Advisory Council. Deverka has a medical degree from the University of Pittsburgh and is board certified in General Preventive Medicine and Public Health.  She also has a master’s degree in bioethics from the University of Pennsylvania and completed a policy fellowship at Duke University’s Institute for Genome Sciences and Policy.

 

ABOUT KATHRYN A. PHILLIPS
Kathryn A. Phillips founded and leads the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), which focuses on developing objective evidence on how to effectively, efficiently, and equitably implement precision/personalized medicine into health care. Kathryn has published over 150 peer-reviewed articles in major journals including JAMA, New England Journal of Medicine, Science, and Health Affairs. She has had continuous funding from NIH as a PI for over 25 years and was recently awarded a 5-year NIH grant to examine payer coverage and economic value for emerging genomic technologies (cell-free DNA tests and tests based on polygenic risk scores). Kathryn serves on the editorial boards for Health Affairs, Value in Health, JAMA Internal Medicine, Genetics in Medicine; is a member of the National Academy of Medicine Roundtable on Genomics and Precision Health; and has served on the governing Board of Directors for GenomeCanada and as an advisor to the FDA, CDC, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to many diagnostics, sequencing, and pharmaceutical companies. Kathryn is Chair of the Global Economics and Evaluation of Clinical Sequencing Working Group, and a member of an evidence review committee for the Institute for Clinical and Economic Review (ICER). 

 

 

Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology

Jun
15
Tue
2021
PHIND Seminar - Pablo E. Paredes, Ph.D. @ Zoom - See description for more information
PHIND Seminar – Pablo E. Paredes, Ph.D.
Jun 15 @ 11:00 am – 12:00 pm Zoom - See description for more information
PHIND Seminar - Pablo E. Paredes, Ph.D. @ Zoom - See description for more information

PHIND Seminar Series: Pervasive Computing With Everyday Devices To Build & Sustain Resilience & Wellbeing

Pablo E. Paredes, PhD
Clinical Assistant Professor, Psychiatry and Behavioral Sciences and, by courtesy, Epidemiology and Population Health
Stanford University

 

Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/99098874758
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Webinar ID: 990 9887 4758
Passcode: 784858

11:00am – 12:00pm Seminar & Discussion
12:00pm – 12:15pm Reception
RSVP Here

 

ABSTRACT
As society progresses towards increasing pervasive computing levels, I design and build technology-enabled solutions to repurpose everyday devices to help people build resilience and grow wellbeing. I leverage biological and behavioral knowledge to design systems that balance user needs and health outcomes while mitigating surveillance and agency risks. In this talk, I present my research on efficacious and engaging sensors and interventions necessary in the population and public health domains. I share a series of research projects exploring and validating novel ideas on passive sensors – less dependent on subjective surveys or wearables –  and subtle interventions that minimize workflow disruption. I show the promise of repurposing existing signals from computing peripherals (i.e., mouse and trackpad) or cars (steering wheel) into “sensorless” sensors and repurposing existing media as just-in-time micro-interventions that can work across multiple scenarios and populations. I discuss how these data could be used in collaboration with domain experts to study topics as varied as the interaction between stress and productivity in office workers, burnout prevention among clinical practitioners, or the prevention of depression among rural health workers. Finally, grounded in theories from neuroscience and behavioral economics, I propose the evolution of everyday “mundane” devices, such as chairs, desks, cars, or even urban lights, into adaptive and autonomous wellbeing-optimizing interventions. I close with a discussion of the research needed to systematically study ethics in pervasive technology for resilience, and wellbeing.

 

ABOUT
Pablo Paredes earned his Ph.D. in Computer Science from the University of California, Berkeley, in 2015 with Prof. John Canny. He is currently a Clinical Assistant Professor in the Psychiatry and Behavioral Sciences Department and the Epidemiology and Population Health Department (by courtesy) at the Stanford University School of Medicine. He leads the Pervasive Wellbeing Technology Lab, which houses a diverse group of students from multiple departments such as computer science, electrical engineering, mechanical engineering, anthropology, neuroscience, and linguistics. Before joining the School of Medicine, Dr. Paredes was a Postdoctoral Researcher in the Computer Science Department at Stanford University with Prof. James Landay. During his Ph.D. career, he held internships on behavior change and affective computing at Microsoft Research and Google. He has been an active associate editor for the Interactive, Mobile, Wireless, and Ubiquitous Technology Journal (IMWUT) and a reviewer and editor for multiple top CS and medical journals. Before 2010, he was a senior strategic manager with Intel in Sao Paulo, Brazil, a lead product manager with Telefonica in Quito, Ecuador, and an entrepreneur in his native Ecuador and, more recently, in the US. In these roles, he has had the opportunity to hire and closely evaluate designers, engineers, business people, and researchers in telecommunications and product development. During his academic career, Dr. Paredes has advised close to 40 mentees, including postdocs, Ph.D., master’s, and undergraduate students, collaborated with colleagues from multiple departments across engineering, medicine, and the humanities, and raised funding from NSF, NIH, and large multidisciplinary intramural research projects.

 

Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology

Jun
21
Mon
2021
International Conference on Functional Imaging and Modeling of the Heart @ Virtual Event
International Conference on Functional Imaging and Modeling of the Heart
Jun 21 – Jun 25 all-day Virtual Event
International Conference on Functional Imaging and Modeling of the Heart @ Virtual Event

Join us for the 11th biennial International Conference on Functional Imaging and Modeling of the Heart (FIMH). FIMH-2021 will celebrate 20 years of bringing together friends, colleagues, and collaborators to share and discuss the latest in cardiac and cardiovascular imaging, electrophysiology, computational modeling, and translational applications. The event will take place June 21-25, 2021 virtually, via Livestream, Zoom meeting workshops, and Spatial Chat networking.

 

Sponsored by: Functional Imaging and Modeling of the Heart Conference

Jun
23
Wed
2021
"The Invisible Future of Health Monitoring" - PHIND & CDH Seminar @ Zoom - See Description for Zoom Link
“The Invisible Future of Health Monitoring” – PHIND & CDH Seminar
Jun 23 @ 3:15 pm – 4:15 pm Zoom - See Description for Zoom Link
"The Invisible Future of Health Monitoring" - PHIND & CDH Seminar @ Zoom - See Description for Zoom Link

PHIND & CDH Seminar: “The Invisible Future of Health Monitoring”

Join Stanford CDH and PHIND on Wednesday, June 23rd at 3:15 PM PDT to hear some of the industry’s leading experts talk about embedded sensors, longitudinal data collection, the future of remote monitoring, and real-world applications of precision health technologies. The panel will feature: Nicolas Genain, MS, WithingsJohn O Moore MD, PhD, Fitbit Health Solutions at GooglePablo Paredes, PhD, MBA, MS, Stanford University; and Michael Synder, PhD, Stanford University. The discussion will be moderated by Jun (Alex) Gao, MS, Samsung America.

 

Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/96984014176
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Webinar ID: 969 8401 4176
Passcode: 375941

3:15pm – 4:15pm: Panel Discussion
RSVP Here

 

 

Sponsored by the PHIND Center and Center for Digital Health

Jul
20
Tue
2021
PHIND Seminar - Alberto Salleo, Ph.D. @ Zoom - See Description for Zoom Link
PHIND Seminar – Alberto Salleo, Ph.D.
Jul 20 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
PHIND Seminar - Alberto Salleo, Ph.D. @ Zoom - See Description for Zoom Link

PHIND Seminar Series: Plastic-based sensors for wearable technologies: fundamentals and applications

 

Alberto Salleo, Ph.D.
Professor of Material Sciences and Engineering
Stanford University

 

Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/92646686705
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Webinar ID: 926 4668 6705
Passcode: 270341

11:00am – 12:00pm Seminar & Discussion
RSVP Here

 

ABSTRACT
The continuous monitoring of human health can greatly benefit from devices that can be worn comfortably or seamlessly integrated in household objects, constituting “health-centered” domotics. One of the key aspects for these devices to be successful is to be invisibly integrated and disappear in the background of our lives. Our group works on thin film devices made with plastic materials that can be used for electrochemically sensing of common analytes from easily accessible bodily fluids (e.g. sweat, saliva, urine) and can be easily multiplexed. I will describe electrochemical transistors that detect ionic species either directly present in body fluids or resulting from a selective enzymatic reaction (e.g. ammonia from creatinine) at physiological levels. I will also show that non-charged molecules can be detected by making use of custom-processed polymer membranes that act as “synthetic enzymes”. Using these membranes in conjunction with electrochemical transistors we demonstrate that we are able to measure physiological levels of cortisol in real human sweat. Importantly, transistors can amplify signals and I will show what architectures must be used to observe 1000x amplification of sensing currents.

Finally we have developed a process that allows us to fabricate sensor arrays on flexible substrates thereby opening the door towards ultra-thin, flexible sensor arrays for wearable technologies.

 

ABOUT
Alberto Salleo is currently Full Professor of Materials Science and Department Chair at Stanford University. Alberto Salleo holds a Laurea degree in Chemistry from La Sapienza and graduated as a Fulbright Fellow with a PhD in Materials Science from UC Berkeley in 2001. From 2001 to 2005 Salleo was first post-doctoral research fellow and successively member of research staff at Xerox Palo Alto Research Center. In 2005 Salleo joined the Materials Science and Engineering Department at Stanford as an Assistant Professor in 2006. Salleo is a Principal Editor of MRS Communications since 2011.While at Stanford, Salleo won the NSF Career Award, the 3M Untenured Faculty Award, the SPIE Early Career Award, the Tau Beta Pi Excellence in Undergraduate Teaching Award, and the Gores Award for Excellence in Teaching, Stanford’s highest teaching award. He has been a Thomson Reuters Highly Cited Researcher since 2015, recognizing that he ranks in the top 1% cited researchers in his field.

 

Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology

Aug
3
Tue
2021
2021 AIMI Symposium + BOLD-AIR Summit @ Virtual Livestream
2021 AIMI Symposium + BOLD-AIR Summit
Aug 3 @ 8:00 am – Aug 4 @ 3:00 pm Virtual Livestream
2021 AIMI Symposium + BOLD-AIR Summit @ Virtual Livestream

Stanford AIMI Director Curt Langlotz and Co-Directors Matt Lungren and Nigam Shah invite you to join us on August 3 for the 2021 Stanford Center for Artificial Intelligence in Medicine and Imaging (AIMI) Symposium. The virtual symposium will focus on the latest, best research on the role of AI in diagnostic excellence across medicine, current areas of impact, fairness and societal impact, and translation and clinical implementation. The program includes talks, interactive panel discussions, and breakout sessions. Registration is free and open to all.

 

Also, the 2nd Annual BiOethics, the Law, and Data-sharing: AI in Radiology (BOLD-AIR) Summit will be held on August 4, in conjunction with the AIMI Symposium. The summit will convene a broad range of speakers in bioethics, law, regulation, industry groups, and patient safety and data privacy, to address the latest ethical, regulatory, and legal challenges regarding AI in radiology.

 

REGISTER HERE

Aug
17
Tue
2021
PHIND Seminar - Orestis Vardoulis, Ph.D. @ Zoom - See Description for Zoom Link
PHIND Seminar – Orestis Vardoulis, Ph.D.
Aug 17 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
PHIND Seminar - Orestis Vardoulis, Ph.D. @ Zoom - See Description for Zoom Link

PHIND Seminar Series: Peace of mind for those affected by stroke

Orestis Vardoulis, Ph.D.
Co-Founder & CEO
ZeitMedical

 

Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/94427469356
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Webinar ID: 944 2746 9356
Passcode: 999031

11:00am – 12:00pm Seminar & Discussion
12:00pm – 12:15pm Reception
RSVP Here

 

ABSTRACT

There is a growing population of over 10 million Americans that live with an elevated risk of having a stroke.

Each year approximately 1 million Americans survive a stroke or a ministroke, often severely affected by its debilitating effects. A more disabling stroke frequently occurs after the seminal events, leaving patients and their families scarred for life.

TIME = BRAIN. Early hospital presentation is the most critical determinant in good stroke outcomes. However, most patients arrive at the hospital often hours after the event, with less than 10% receiving any form of treatment (thrombolysis / thrombectomy).

As a result, at risk individuals struggle daily with the fear, a stroke might happen during night-time or when they are alone. Unfortunately a stroke that goes unnoticed for hours, is most often not treatable due to the lack of salvageable tissue.

To alleviate that fear, we are creating an AI-powered, smart-headband that analyzes brain waves to detect the onset of an event immediately, and alert the patient, caregivers and 911.

Our stroke detection AI has already been shown to detect ischemia during high-risk surgeries with 90% sensitivity and no false positives.

We have received FDA breakthrough designation for our solution and are currently running a pilot human factors and signal quality study.

Our vision is to provide peace of mind and optimal brain health for everyone.

 

ABOUT
Orestis is the CEO and Co-founder of Zeit Medical, a telehealth company that offers at home monitoring and alert solutions for patients at risk for stroke. Prior to starting Zeit, Orestis was a Stanford Biodesign Innovation Fellow where his team developed the initial idea about at-home stroke detection. Orestis trained as a Mechanical Engineer, at Aristotle University, Greece, earned his PhD in Biotechnology and Bioengineering at EPFL, Switzerland and conducted cutting edge research in flexible wearable electronics with the Bao Group at Stanford Chemical Engineering. He has authored more than twenty publications in prestigious journals and has filed for a variety of patents at the intersection of materials technology and medical devices. Orestis currently lives in San Francisco, where he also contributes to the UCSF-Stanford pediatric device consortium as a technology advisor.  He also maintains close ties with the med-tech and health-tech communities in Switzerland and Greece, contributing to regional Biodesign educational workshops.

 

Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology

Sep
10
Fri
2021
CME Grand Rounds Sanjiv Sam Gambhir Lectureship - Simon Cherry, PhD @ LKSC 101/102 & Zoom - See Description for Zoom Link
CME Grand Rounds Sanjiv Sam Gambhir Lectureship – Simon Cherry, PhD
Sep 10 @ 12:00 pm – 1:00 pm LKSC 101/102 & Zoom - See Description for Zoom Link
CME Grand Rounds Sanjiv Sam Gambhir Lectureship - Simon Cherry, PhD @ LKSC 101/102 & Zoom - See Description for Zoom Link

CME Grand Rounds Sanjiv Sam Gambhir Lectureship – “Imaging at the Speed of Light:  Innovations in Positron Emission Tomography”

 

Simon R. Cherry, PhD
Professor
Biomedical Engineering & Radiology
UC Davis

 

Join from PC, Mac, Linux, iOS or Android: https://stanford.zoom.us/j/600003703?pwd=RjcwS2MvOG1qVkxyL3U0RmNtUDVWdz09
Meeting ID: 600 003 703
Password: 566048
Or iPhone one-tap (US Toll): +18333021536,,600003703# or +16507249799,,600003703#
Or Telephone:
Dial: +1 650 724 9799 (US, Canada, Caribbean Toll) or +1 833 302 1536 (US, Canada, Caribbean Toll Free)
International numbers available: https://stanford.zoom.us/u/acuqphnvqT

 

ABSTRACT

Positron emission tomography (PET) allows for sensitive and quantitative measurement of physiology, metabolism and molecular targets noninvasively in the human body.  However, typical clinical PET scanners capture less than 1% of the available signal produced in the body.  PET scanners also are not currently capable of precisely determining the location at which a particular decay occurs. These limitations present opportunities for further innovation that ultimately will impact molecular imaging research and diagnostic imaging with PET.  This presentation focuses on 1) total-body PET imaging which greatly improves signal collection, allowing radiotracer kinetics to be assessed across the entire human body for the first time, and 2) the development of detector technologies that have a timing precision of ~ 30 picoseconds, enabling direct localization of radiotracer decays without tomographic reconstruction.

 

BIO

Simon R. Cherry, Ph.D.  received his B.Sc.(Hons) in Physics with Astronomy from University College London in 1986 and a Ph.D. in Medical Physics from the Institute of Cancer Research, University of London in 1989.  After a postdoctoral fellowship at UCLA, he joined the faculty in the Department of Molecular and Medical Pharmacology, also at UCLA, in 1993. In 2001, Dr. Cherry joined UC Davis and established the Center for Molecular and Genomic Imaging, which he directed from 2004-2016. Currently Dr. Cherry is Distinguished Professor in the Departments of Biomedical Engineering and Radiology at UC Davis.

Dr. Cherry’s research interests center around biomedical imaging and in particular the development and application of in vivo molecular imaging systems.  His major accomplishments have been in developing systems for positron emission tomography (PET), in particular the invention of the microPET technology that was subsequently widely adopted in academia and industry and as co-leader of the EXPLORER consortium which has developed the world’s first total-body PET scanner.  He also has contributed to detector technology innovations for PET, conducted early biomedical studies using Cerenkov luminescence, and developed the first proof-of-concept hybrid PET/MRI (magnetic resonance imaging) systems.

Dr. Cherry is a founding member of the Society of Molecular Imaging and an elected fellow of six professional societies, including the Institute for Electronic and Electrical Engineers (IEEE) and the Biomedical Engineering Society (BMES). He served as Editor-in-Chief of the journal Physics in Medicine and Biology from 2011-2020. Dr. Cherry received the Academy of Molecular Imaging Distinguished Basic Scientist Award (2007), the Society for Molecular Imaging Achievement Award (2011) and the IEEE Marie Sklodowska-Curie Award (2016).   In 2016, he was elected as a member of the National Academy of Engineering and in 2017 he was elected to the National Academy of Inventors.  Dr. Cherry is the author of more than 240 peer-reviewed journal articles, review articles and book chapters in the field of biomedical imaging. He is also lead author of the widely-used textbook “Physics in Nuclear Medicine”.